HYD1 peptides as anti-cancer agents

Details HYD1 peptides as anti-cancer agents HYD1 peptides as anti-cancer agents

2007-09-07

2009-12-15

Helms, Larry R. (Department: 1643)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S300000

Reexamination Certificate

active

07632814

ABSTRACT:
The present invention concerns fragments and variants of the HYD1 peptide; polynucleotides encoding the peptides; host cells genetically modified with the polynucleotides; vectors comprising the polynucleotides; compositions containing these peptides, polynucleotides, vectors, or host cells; and methods of using the peptides, polynucleotides, vectors, and host cells as inhibitors of aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as myeloma. The present invention further includes a method of increasing the efficacy of chemotherapy and radiation therapy, comprising administering an agent that binds β1 integrin to a patient in need thereof. In one embodiment, the β1 integrin binding agent is the HYD1 peptide, or a functional fragment or variant thereof. In another aspect, the invention pertains to a composition (an adhesion trap) comprising a substrate (also referred to as a surface or support) with a HYD1 peptide, or fragment or variant thereof, immobilized to the substrate, and a method of removing circulating tumor cells (CTC) from blood by contacting a subject's blood with the immobilized peptide. Another aspect of the invention concerns a method of identifying modulators of peptide binding. Another aspect of the invention concerns a method for detecting CTC.

REFERENCES:
patent: 6849712 (2005-02-01), McCarthy et al.
patent: 2004/0096906 (2004-05-01), Lam et al.
patent: 2006/0019900 (2006-01-01), Lam et al.
patent: WO0162776 (2001-03-01), None
patent: WO 2005/045430 (2005-05-01), None
Aoudjit F, Vuori K. Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells.Oncogene.2001;20:4995-5004.
Astier A, Manie SN, Avraham H, et al. The related adhesion focal tyrosine kinase differentially phosphorylates p130Cas and the Cas-like protein, p105HEF1.J Biol Chem.1997;272:19719-19724.
Chen Q, Lin TH, Der CJ, Juliano RL. Integrin-mediated activation of MEK and mitogen-activated protein kinase is independent of Ras [corrected].J Biol Chem.1996;271:18122-18127.
Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines.Blood. 1999;93:1658-1667.
Damiano JS, Hazlehurst LA, Dalton WS. Cell adhesion-mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR/ABL inhibition, cytotoxic drugs, and gamma-irradiation.Leukemia. 2001;15:1232-1239.
Deroock IB, Pennington ME, Sroka TC, et al. Synthetic peptides inhibit adhesion of human tumor cells to extracellular matrix proteins.Cancer Res.2001;61:3308-3313.
Hannigan GE, Leung-Hagesteijn C, Fitz-Gibbon L, et al. Regulation of cell adhesion and anchorage-dependent growth by a new beta 1-integrin-linked protein kinase.Nature. 1996;379:91-96.
Hazlehurst LA, Argilagos RF, Dalton WS. β1 integrin adhesion increases Bim protein degradation and confers drug resistance in leukemia cellsBritish Journal Haematology. 2006.
Hazlehurst LA, Argilagos RF, Emmons M, et al. Cell adhesion to fibronectin (CAM-DR) influences acquired mitoxantrone resistance in U937 cells.Cancer Res.2006;66:2338-2345.
Hazlehurst LA, Damiano JS, Buyuksal I, Pledger WJ, Dalton WS. Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR).Oncogene. 2000;19:4319-4327.
Hazlehurst LA, Enkemann SA, Beam CA, et al. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model.Cancer Res.2003;63:7900-7906.
Hazlehurst LA, Valkov N, Wisner L, et al. Reduction in drug-induced DNA double-strand breaks associated with beta1 integrin-mediated adhesion correlates with drug resistance in U937 cells.Blood. 2001;98:1897-1903.
Hazlehurst LA, Targeting beta1 Integrins in Multiple Myeloma. Presentation atAdvancing Myeloma Therapy: Translating Laboratory Concepts Into Clinical Reality Symposium held in conjunction with the XIthInternational Myeloma Symposium. Jun. 25, 2007.
King WG, Mattaliano MD, Chan TO, Tsichlis PN, Brugge JS. Phosphatidylinositol 3-kinase is required for integrin-stimulated AKT and Raf-1/mitogen-activated protein kinase pathway activation.Mol Cell Biol.1997;17:4406-4418.
Lwin T, Hazlehurst LA, Dessureault S, et al. Cell adhesion induces p27Kip1-associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle cell and other non-Hodgkin's B-cell lymphomas.Blood. 2007.
Nefedova Y, Landowski TH, Dalton WS. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms.Leukemia. 2003;17:1175-1182.
Pennington ME, Lam KS, Cress AE. The use of a combinatorial library method to isolate human tumor cell adhesion peptides.Mol Divers. 1996;2:19-28.
Schaller MD, Parsons JT. pp125FAK-dependent tyrosine phosphorylation of paxillin creates a high-affinity binding site for Crk.Mol Cell Biol.1995;15:2635-2645.
Schlaepfer DD, Hanks SK, Hunter T, Van Der Geer P. Integrin-mediated signal transduction linked to Ras pathway by GRB2 binding to focal adhesion kinase.Nature. 1994;372:786-791.
Sethi T, Rintoul RC, Moore SM, et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo.Nat Med.1999;5:662-668.
Sroka TC, Marek J., Pennington ME, Lam KS The Minimum Element of a Synthetic Peptide Required to Block Prostate Tumor Cell MigrationCancer Biology&Therapy2006; 5: 11: 1556-1562.
Sroka TC, Pennington ME, Cress AE. Synthetic D-amino acid peptide inhibits tumor cell motility on laminin-5.Carcinogenesis. 2006.
Van Riet I, De Waele M, Remels L, Lacor P, Schots R, Van Camp B. Expression of cytoadhesion molecules (CD56, CD54, CD18 and CD29) by myeloma plasma cells.Br J Haematol. 1991;79:421-427.
Yaccoby S, Barlogie B, Epstein J. Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations.Blood. 1998;92:2908-2913.
Zhu K, Gerbino E, et al. Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells.Blood. 2005;105:4759-4766.

Affiliated with

Also associated with

Rating

HYD1 peptides as anti-cancer agents does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with HYD1 peptides as anti-cancer agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HYD1 peptides as anti-cancer agents will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4139757